Photo of Philip Friedlander
Accepting New Patients
Philip Friedlander, MD, PhD
    • Positions
    • ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
    • ASSISTANT PROFESSOR | Dermatology
    • Specialties
    • Oncology
    • Hematology-Oncology
    • Internal Medicine
    • Language
    • English
    • Hospital Affiliations
    • Mount Sinai Beth Israel
    • The Mount Sinai Hospital
    • Phone
    • Ruttenberg Treatment Center 212-241-6756
Request an Appointment
1470 Madison Avenue 3rd floor
New York, NY 10029
Phone: 212-241-6756
Dr. Friedlander received medical school training at Columbia University where he obtained his M.D. and Ph.D. degree in  Biology. He remained at Columbia Presbyterian Medical Center to complete his postdoctoral training in Internal Medicine and subsequently completed a clinical fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. He then joined the faculty of the Dana Farber Cancer Institute/Brigham and Women’s Hospital as an attending physician within the Melanoma and Cutaneous Oncology Programs and as an Instructor of Medicine at Harvard Medical School.  His clinical interests include the development of targeted therapies and immunotherapies for patients with melanoma, merkel cell carcinoma, advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and sebaceous gland tumors.  At the Dana Farber Cancer Institute he acted as a principal investigator testing novel therapeutic approaches for melanoma including PARP inhibition, hsp90 inhibition, anti-apoptotic approaches, and immune modulatory and anti-CTLA4 based strategies. He investigated in non-melanoma skin cancers novel therapeutic strategies such as hedgehog signaling pathway inhibition in advanced basal cell carcinoma.  As a member of the Division of Hematology/Medical Oncology and as the Director of the Melanoma Medical Oncology Program at Mount Sinai, he will be caring for patients with cutaneous malignancies and continue working to develop collaborative translational and basic science  projects  and treatments for patients with cutaneous malignancies.  

In the News:

Watch Dr. Friedlander discuss a new FDA approved treatment (Erivedge) for Basal Cell Carcinoma:
KTVX-TV (ABC/Salt Lake City, Utah) 
KRNV-TV (NBC/Reno, Nevada)
WNAV-AM (Baltimore, Maryland)

Clinical Focus


MD, Columbia University

Internship, Internal Medicine
Columbia-Presbyterian Medical Center

Residency, Internal Medicine
Columbia-Presbyterian Medical Center

Fellowship, Oncology
Memorial Sloan-Kettering Cancer Center